Kymera Therapeutics Management
Management criteria checks 2/4
Kymera Therapeutics' CEO is Nello Mainolfi, appointed in Jun 2019, has a tenure of 5.5 years. total yearly compensation is $9.67M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 1% of the company’s shares, worth $26.43M. The average tenure of the management team and the board of directors is 3.6 years and 4 years respectively.
Key information
Nello Mainolfi
Chief executive officer
US$9.7m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 5.5yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Kymera: Protein Degradation Could Drive Dupixent-Like Value
Dec 07Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 04
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Oct 06Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$167m |
| Jun 30 2024 | n/a | n/a | -US$158m |
| Mar 31 2024 | n/a | n/a | -US$155m |
| Dec 31 2023 | US$10m | US$640k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$167m |
| Jun 30 2023 | n/a | n/a | -US$158m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$7m | US$600k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$139m |
| Mar 31 2022 | n/a | n/a | -US$124m |
| Dec 31 2021 | US$12m | US$571k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$4m | US$454k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$57m |
| Mar 31 2020 | n/a | n/a | -US$52m |
| Dec 31 2019 | US$2m | US$362k | -US$41m |
Compensation vs Market: Nello's total compensation ($USD9.67M) is above average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Nello's compensation has increased whilst the company is unprofitable.
CEO
Nello Mainolfi (45 yo)
5.5yrs
Tenure
US$9,670,542
Compensation
Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.3yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5.5yrs | US$9.67m | 1% $ 26.4m | |
| Chief Financial Officer | 5.4yrs | US$4.16m | 0.18% $ 4.8m | |
| Chief Operating Officer | 1.6yrs | US$5.19m | 0.0089% $ 234.1k | |
| Chief Legal Officer & Corporate Secretary | 1.9yrs | US$4.97m | 0.0094% $ 247.3k | |
| Chief Medical Officer | 6.3yrs | US$3.47m | 0.084% $ 2.2m | |
| Head of People & Culture | 2.6yrs | no data | no data | |
| Head of Research | 3.6yrs | no data | no data |
3.6yrs
Average Tenure
59yo
Average Age
Experienced Management: KYMR's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 9.3yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 5.1yrs | US$9.67m | 1% $ 26.4m | |
| Independent Director | 2.9yrs | US$236.46k | 0% $ 0 | |
| Lead Independent Director | less than a year | no data | no data | |
| Independent Director | 3.8yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$241.46k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$243.96k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$231.46k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$236.46k | 0% $ 0 |
4.0yrs
Average Tenure
51.5yo
Average Age
Experienced Board: KYMR's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Etzer Darout | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |